265 related articles for article (PubMed ID: 29741634)
1. Serum HBV RNA as a Predictor of Peginterferon Alfa-2a Response in Patients With HBeAg-Positive Chronic Hepatitis B.
van Bömmel F; van Bömmel A; Krauel A; Wat C; Pavlovic V; Yang L; Deichsel D; Berg T; Böhm S
J Infect Dis; 2018 Aug; 218(7):1066-1074. PubMed ID: 29741634
[TBL] [Abstract][Full Text] [Related]
2. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
Jia W; Zhu MQ; Qi X; Wang T; Wen X; Chen PD; Fan QQ; Zhang WH; Zhang JM
Virol J; 2019 May; 16(1):61. PubMed ID: 31064399
[TBL] [Abstract][Full Text] [Related]
3. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
[TBL] [Abstract][Full Text] [Related]
4. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
Lau GK; Piratvisuth T; Luo KX; Marcellin P; Thongsawat S; Cooksley G; Gane E; Fried MW; Chow WC; Paik SW; Chang WY; Berg T; Flisiak R; McCloud P; Pluck N;
N Engl J Med; 2005 Jun; 352(26):2682-95. PubMed ID: 15987917
[TBL] [Abstract][Full Text] [Related]
5. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
[TBL] [Abstract][Full Text] [Related]
7. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
[TBL] [Abstract][Full Text] [Related]
8. Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.
Brunetto MR; Marcellin P; Cherubini B; Yurdaydin C; Farci P; Hadziyannis SJ; Rothe V; Regep L; Bonino F
J Hepatol; 2013 Dec; 59(6):1153-9. PubMed ID: 23872601
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
Marcellin P; Lau GK; Bonino F; Farci P; Hadziyannis S; Jin R; Lu ZM; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Button P; Pluck N;
N Engl J Med; 2004 Sep; 351(12):1206-17. PubMed ID: 15371578
[TBL] [Abstract][Full Text] [Related]
10. Early serum hepatitis B virus large surface protein level: a stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B.
Zhu X; Gong Q; Yu D; Zhang D; Gu L; Han Y; Chen J; Zhang Y; Zhang X
J Clin Virol; 2013 Aug; 57(4):318-22. PubMed ID: 23639294
[TBL] [Abstract][Full Text] [Related]
11. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.
Brunetto MR; Moriconi F; Bonino F; Lau GK; Farci P; Yurdaydin C; Piratvisuth T; Luo K; Wang Y; Hadziyannis S; Wolf E; McCloud P; Batrla R; Marcellin P
Hepatology; 2009 Apr; 49(4):1141-50. PubMed ID: 19338056
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
[TBL] [Abstract][Full Text] [Related]
14. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
15. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
17. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.
Zhang M; Li G; Shang J; Pan C; Zhang M; Yin Z; Xie Q; Peng Y; Mao Q; Xiao X; Jiang Y; Luo K; Xu Y; Ding H; Fan W; Diego V; Pourkarim MR; De Clercq E; Wang G; Gong G
Hepatol Int; 2020 Mar; 14(2):212-224. PubMed ID: 32100261
[TBL] [Abstract][Full Text] [Related]
18. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Gish RG; Lau DT; Schmid P; Perrillo R
Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
